C-Rad AB (publ) (CRADB) Earnings Call Transcript & Summary

Morning, everyone, and welcome to C-RAD's presentation of the year-end report for the year 2021. My name is Priscilla Kazumba, and I will be moderating today's webcast. The report will be presented to you by Tim Thurn, our CEO; and Henrik Bergentoft, the CFO. The presentation will address the fiscal year 2021 with a focus on the fourth quarter. Tim will start off with a short introduction and comment on the financial highlights, followed by an analysis of the sales development before he finishes with commenting on the key events. Henrik will guide you through the financial review before he hands the microphone back to Tim, who will conclude the presentation with a short overview of the market. Before we close the webcast, there is an opportunity to ask questions. [Operator Instructions] We will not respond to any questions in the chat. So please, if you have any questions, you can use the raise your hand button. Outside the Q&A session, all participants are muted. A recording of the webcast will be available on the C-RAD's website after the presentation. And therewith, I hand over the word to Tim.

Thank you very much for the introduction. Let's get started with an introduction of the financial highlights. C-RAD is active in the field of cancer treatment. Our customers are hospitals that fight cancer with radiation. A modern, high-precision radiation therapy, accurate tumor alignment is crucial for a safe and successful treatment. A very good example is the treatment of breast cancer patients. Here, the tumor is located very close to the heart. Radiation to the heart might cause severe damages to the functionality of the organ. C-RAD's products help to control the radiation, so the beam is only switched on when the tumor and the heart are in the correct position. The cost for this safety are less than 5% of the investment for a new treatment room. C-RAD positioning products are supporting this process and are fully integrated in the clinical workflow. Over the past years, C-RAD has been growing significantly and generated last year more than SEK 260 million in revenue and an operating margin of approximately 14%. Next slide. We have done great progress towards our goal of establishing surface tracking technology as the standard of care in advanced radiation therapy. We are delivering a quarter and full year with a record high in all key metrics, order intake, revenue and operating profit. An achievement despite the increasingly challenging supply chain situation and the again rising implications of the pandemic. The comparable in 2020 are high for order intake and revenue, but we are booking SEK 132.9 million in orders, an increase of 9% compared to the fourth quarter 2020. Revenue went up to SEK 77.4 million, leaving us with an order backlog of SEK 420 million comparison to SEK 350 million in the year before. With the revenue and further improved gross margin, the business is generating an operating income of SEK 14.9 million or 19.3% points, a significant improvement compared to the previous year. The net result after tax amounted to SEK 11.4 million or SEK 0.34 per share. Once again, very good progress also in the fourth quarter. Next slide, please. Let's take a closer look at our sales performance. Next slide. This slide is showing the order intake for the fourth quarter on the left side and the full year on the right chart. The North American market is delivering a 29% growth in order intake for the full year. There is a huge potential for our technology and with our setup and the partnership with Elekta, C-RAD is well positioned to exploit this potential. It should be noted that during 2020, about 2/3 of the orders were booked in Q4 because of projects being stalled as a consequence of the pandemic in the North American market. After a pretty flat development in the first half of 2021, the EMEA region gained again momentum in the second half of 2021, especially Germany and the Benelux countries contributed measurable to this development. The APAC region continued to be affected by the pandemic, especially in Australia where projects were stalled. Considering a very successful order intake from Japan and Australia in 2020, it affects the result for the region comparing the full year 2020 and 2021. And we are reporting a minor decline in order intake. But again, a 24% growth in Q4. Our investment to establish an office in Delhi in India has shown first results in terms of orders with expected installations during the first half of 2022. China is the largest market for us in the APAC region continues to show steady growth. In December, we received yet another order from the Belgian company, IBA, for 2 proton therapy projects in China. We see volatility in various regions. However, the underlying trend is pointing in the right direction. Next slide, please. Our business reflected an order intake and especially in order intake -- excuse me, reflected in revenue and especially in order intake is subject to a very distinct seasonality pattern, where usually the second half of the year is significantly stronger than the first 2 quarters. This is since many customers are hospitals and clinics, which have annual budget cycles that are in line with the calendar year and usually pursue their purchasing projects before the New Year commences. Next slide, please. The left chart is showing revenue by region for Q4, and the right chart displays the full year perspective by region. Across all regions, revenue increased with 80% for the full year, which is a very satisfying result. The enforced order intake in the Americas commencing towards the end of 2020 has contributed to a full year revenue growth of 75%, a measurable part of the company's total growth for the year. With again, short book and build periods, the growing order intake translates to 42% revenue growth in the quarter and 23% for the full year in the EMEA region. I mentioned the high order intake in the beginning of 2020 from Japan and Australia. Projects were partly delivered in Q4 last year, which is the reason for the 40% revenue decline in the region. Again, one example of the volatility that our business is exposed to. Next slide. This slide displays the revenue by product category for the year 2021. I'm proud to say that we succeeded to grow all our product category revenue during this year. Very encouraging and underlining that C-RAD is well positioned with its product portfolio. Our largest product category, the sales of positioning products grew 16%. Revenue in our service business for life cycle business, as we call it, grew with impressive 40%. If I may point your attention to the chart on the right side, it displays the service revenue as a percentage of the total revenue. We see an encouraging development, whereas the category has been growing from approximately 4% to a share of 13% over the past 4 years. Usually, service contracts are commitments from the customer to obtain service from C-RAD for a period of an average 3 to 5 years. Next slide, please. Looking at the radiation therapy and the clinical measures taken during the pandemic have certainly accelerated the implementation of high-precision treatment techniques, so-called stereotactic and hypofractionated treatments. For safe and efficient delivery, customers use surface tracking technology to position and to monitor patient during the treatment. This development makes us very confident that the demand of our technology will continue to grow moving forward and will become part of the standard of care for such treatments, meaning that the majority of all linear accelerators by default will be equipped with surface tracking equipment. This slide is showing the development in order intake and revenue over the past 5 years. Next slide. Coming to the key events during the period. Next slide. In December, C-RAD received a purchase order from the Belgium company, IBA, to supply multiple Catalyst systems and Sentinel systems as well as a multiyear service contract for 2 sites in China. This order is another milestone in a successful cooperation. C-RAD and IBA have several projects at multiple sites globally. Proton therapy is considered to be the spearhead when it comes to high-precision radiation therapy. Treatments demand for uncompromised security and operational efficiency, which lies in the center of the technology advancement of C-RAD. One of many reasons why C-RAD is the SIGRT market leader within the field of proton therapy. Next slide, please. C-RAD and Elekta took the next step to drive compatibility between each other systems. The integration of Elekta's latest linac Harmony has been successfully validated and the first installation of customer sites have been completed. Once more C-RAD is pioneering and we are proud that Catalyst+ HD can be offered in all Elekta linac customers which is part of our goal to establish surface tracking as the standard of care. Interoperability and connectivity are crucial for efficient and safe patient treatments, and we are excited to see Catalyst HD contribution to Elekta Harmony treatment success. The systems are a great fit, as Elekta says, Harmony is designed to allow centers to increase patient throughput without compromising on precision and versatility to treat a wide patient population. And Catalyst is used to increase safety and drive efficiency in the clinical work field. Next slide. Therewith, I hand over the microphone to Henrik, who will guide you through the financial review.

Thank you so much, Tim. And Priscilla, may I ask you to move to the next slide. And let's start off with a closer look at our P&L statement. So as said, revenues grew 4% in the quarter to SEK 77.4 million. In constant currencies, the growth was and all compared to a very strong Q4 last year. For the full year, revenue increased with 18% to SEK 261.2 million, 21% in constant currencies. The gross margin for the quarter came in at a strong 66%. I will add some further comments on that on the following slide. External expenses for the quarter amounted to SEK 14.5 million compared to SEK 14.1 million same quarter last year. For the full year, operating expense was SEK 52.5 million compared to SEK 44.3 million last year. It should be noted that last year's total external expenses were significantly impacted by the pandemic with virtually no travel or physical market events taking place. That has in some extent been resumed during 2021. Personnel expenses for the quarter amounted to SEK 20.1 million compared to SEK 15.8 million last year. And for the full year, SEK 71.7 million compared to SEK 64.8 million. To be noted here is that last year, we had pandemic-related governmental support in various regions, which then, of course, reduced our personnel expenses. Key driver behind the increased personnel expenses is that the average number of employees amounts to SEK 66 million during the fourth quarter 2021 compared to SEK 56 million during the corresponding period in 2020. At the end of 2021, the number of employees in the group amounts to 66 as compared to 55 last year. All combined, the operating income for the quarter amounted to SEK 14.9 million compared to SEK 9.8 million last year corresponding to a margin of 19.3% compared to 13.2% last year. For the full year, the operating income amounted to SEK 36 million more than doubling from last year's SEK 17 million and producing a margin of almost 14% compared to almost 8% last year. The increase in the operating income and improved margins is a function of the growth in revenue with improved gross margins and cost control in general. Next slide, please. So this slide displays revenue and our gross margin over a longer period of time. And as said, gross profit margin came in at 66% during the fourth quarter in 2021 compared to 58% last year. For the full year, gross product margin was 63% compared to 59% last year. To be noted is that cost of goods sold in the fourth quarter 2020 included commission to sales channel partners of almost SEK 3 million. Hence, the underlying gross margin in 2020 was 60% in the quarter and 60% for the full year. Fluctuations in the gross profit margin can be expected between periods as it is dependent on a couple of factors. One being the product mix and the other one is the variation of sales channels in our different markets. Where we, in the fourth quarter, had a larger portion of direct sales, which was the driver behind the improved gross margin in the fourth quarter. Next slide, please. In the current quarter and for the full year, we saw a revenue growth combined with increased operating profit, both in absolute and relative terms. And the message of this slide is to show that this is a trend actually built up over time, where C-RAD has been investing in the organization to support growth, which, of course, has generated an increase in operating expenses over the time. But the graph outlines that these investments are, in fact, paying off in the sense that the revenue trend line has a steeper upward leaning curve as compared to operating expenses. Equally, meaning that the average yearly operating expense in relation to sales is going down ultimately generating what we presented now in the quarter and for the full year, growth with increased profitability. Next slide, please. This slide shows just that our operating profit and revenue over a longer period of time. And as seen, the business of C-RAD is volatile between the quarters and expect it to be so going forward since larger single order has an effect in the quarter when they are delivered, combined with a seasonality pattern with a stronger second half of the year. That said, the trend line clearly shows that C-RAD is on a growth journey. And since mid-2018, it is a profitable growth journey with significantly improved operating margins starting in the fourth quarter 2020, and this trend continuously improved during 2021 with a record high operating margin of 19% in the fourth quarter of 2021. Next slide, please. So this slide displays our cash flow and our balance sheet as it stands for the end of 2021 with a couple of comments to be made on the balance sheet. We have a relatively low level of material assets. We are a debt-free company, and we have a solidity ratio of 77%. On the cash flow side, our positive operating profit is also generating a positive cash flow for the full year and the quarter. ending the year with SEK 122 million in liquid funds. And in addition to that, the company has an unused credit facility of SEK 20 million. Next slide, please. So this slide displays our order backlog at the end of 2021. And as I think most of you know, the order backlog represents orders that have been received but not yet delivered nor invoiced or recognized as revenue. So this represents our future revenue. The backlog amounted to SEK 425 million at the end of the quarter, an increase of 21% compared to the same period last year. From the total order backlog, about half of it relates to products, SEK 212 million and the other half SEK 213 million relates to our service contracts or the life cycle business. Of the life cycle business order backlog, SEK 31.6 million, representing 15% of that order backlog is programmed to be recognized as revenue within the coming 12 months period as the service contracts are recognized as revenue over the contract period. The service contract can be up to 8 years, while the most common contract period is 3 to 5 years. And by that, I would like to close the financial part of this presentation and hand the microphone over back to Tim.

Great. Henrik, thank you very much. Let's move on to the next slide, Priscilla. I would like to give a short overview about C-RAD and our business. C-RAD is part of the fight against cancer. Cancer is among the leading causes of death worldwide. Three methods have been established to treat cancer, which is surgery, drug therapy or chemotherapy and radiation therapy. C-RAD is active in the field of radiation therapy and our products are used to improve patient safety and increase efficiency. The demand for our products is driven by the worldwide implementation of high-precision treatment techniques. C-RAD solution significantly decreases the risk for the patient to suffer from radiation injuries. For approximately 5% of the additional cost of the total investment into a new treatment room, we position the C-RAD equipment. Next slide, please. The technology is on its way to become standard of care, and there are several indications in the market that underline our assessment. With almost all tenders in -- for new linear accelerators in the Western world, surface tracking is part of the discussion in such tenders. And a very good example, I think I mentioned it already in the last webcast is a tender that was released this -- or last year 2021 by the Spanish government for replacing around 80 linacs in the entire country. This tender made it mandatory that these linacs are equipped with surface tracking. This was also an important confirmation for us that interest and the message gets through that it truly becomes standard of care. Another indication is the major vendors, all major vendors of linear accelerators, Varian, Elekta, Accuray have different ways, started to incorporate positioning products into their product catalogs. And the last point that I want to make is the technology or the spearhead in terms of precision radiation therapy is proton therapy. And I mean, what we can see is that essentially in all new proton therapy centers surface tracking is part of what is going to be implemented, plus existing centers that are not yet equipped with surface tracking are equipping their centers with surface tracking. So all very positive indications for us to make this technology standard of care. Next slide, please. Another angle to look at the standard of care is look at the clinical adoption. Whereas in 2015, the focus for surface tracking was only on breast treatment. That was the first indication where surface tracking was clinically implemented. However, if we compare that to the implementation in 2020, we see a significant increase, and it is used for more than 70% of the patients that are receiving radiation therapy at a given center. So it moved from breast only to a very versatile solution that is used for a large priority of indications. Move on. If we look at the underlying trend, I mentioned before the stereotactic, the high-precision radiation therapy, the high-precision treatment techniques, there's a very clear trend globally ongoing to move from the conventional treatment, which require roughly 30 treatment sessions towards this high-precision treatment session where only up to 10, 15 treatment sessions are required. So there's a very clear trend that was accelerated due to the pandemic over the past years. We move on to the next slide and look at the market potential. By now, C-RAD has sold approximately 800 systems worldwide. The annual sales volume of new linacs is approximately 1,300 linacs. If we keep the current price levels and if the attachment rate follows my assessment, the market potential is approximately SEK 1 billion per year. We believe that we are able to capture a best part of the potential. If we would capture half of the market would translate into around SEK 500 million in revenue. This is a conservative calculation and does not include the service opportunity that we discussed earlier. It does not include the retrofit, meaning the installed base of linacs upgrading the installed base and the overall growth of the linac sales. With the current gross margin and the cost structure growing at the lower rate as revenue, we would increase profitability over time even further. If we take a look at the clinical advantages of the technology, first of all, it is a dose free way of positioning the patient. There are other ways how the patient can be positioned, but the advantage of the C-RAD solution is that it is dose free, which translates into less side effects for the patient. It is noninvasive, which clearly translates into an ease of use for the user, for the operator. Looking back to the patient, it is markerless. Alternative system require marks or tattoos on the patient which is not required with the C-RAD system, translating into a huge benefit in the patient comfort. Less impact on the daily workflow. C-RAD has put special attention on integrating the system in the best possible way in the surrounding environment, which clearly translates into usability advantages for the operator. And last but not least, the patient compliance. With the technology that we have used, it is possible to use that in a standardized workflow, meaning it can be used essentially on all patients. Next slide. If we look at our business model, I mean, the focus for us is -- our focused customers are advanced radiation therapy clinics. And essentially, we are approaching them through 3 sale channels. A large part is still the direct sales, meaning our own sales organization, our own service organization is working directly with the customers. In certain countries, we have distributors that are independent resellers that distribute our products towards the end customers. But then we have also engaged several OEM partnerships where we enabled the OEM to put the product into the price book and sell it as part of a package towards the customer, together with their linac. Next slide, please. If we look at our strategy, it is basically based on 3 pillars: the product excellence, the sales excellence and the service excellence. Looking at the product excellence. I think the clinical applications are clearly rendered. We have -- we know what the clinical trends are and surface tracking is a natural fit to improve the treatment quality and reduce the risk for the patient. We have the clinical message. Now it is about getting the message out in the market to talk to the customers, to get them excited about the C-RAD solution. If we look on the next slide on the service side, we made significant progress to sell all the service contracts together with the systems. What we see is an increased interest from customers to not service the systems themselves, but rather outsource that to the manufacturers. And that's an attractive business for us. Last year, the service business, as we had earlier, was growing with 40% in revenue. Order intake amounted to SEK 82 million in service revenue. If we look -- sorry, in service orders. If you look at the global attachment rate, we still see that the large majority, I think it's around 92% of the customers in the U.S. right now sign up for service contracts. In EMEA, we are north of 40 -- sorry, 60% of the customers that decided for service contracts. If we look to the APAC region, it really depends on the market, whereas in Japan, we see a huge interest. Australia, we see a huge interest in service contracts. There are other markets where especially China, where the interest in service contracts at this stage is not that significant. Move on to the next slide. So if you look at the C-RAD case, I think there are a few points why an investment in C-RAD makes sense. First of all, I mean, C-RAD brings measurable value for the society in the fight against cancer. C-RAD has a proven and recognized product. We have established the C-RAD products. We have established the product all over the world, essentially all over the world and presented the clinical benefits to the society. C-RAD has a comprehensive market access through the direct sales organization distributors, but now newly also with the OEM vendors. And there are several factors that point towards surface tracking becoming standard of care. And last but not least, C-RAD has a very stable financial platform, C-RAD is debt free, and we have more than SEK 100 million in cash on the bank. Next slide. We wanted to give an update to the financial calendar. I specifically want to invite you to investor presentation, investor meetings that we have planned in March and May. On the 10th of March, we are participating in the Erik Penser Capital Markets Day. And on mid of May, May 18, we are participating at the ABG Annual Life Science Summit. So I would be happy to welcome you on one of the events. So -- and then we have the possibility to ask questions. Move on the next slide. As Priscilla said, please raise the hand and then we will open the microphone and then you can address your questions. Thank you very much.

Well, we have Chad Schwartz, who would like to ask a question. So I will unmute you. Can you hear us? I think you just have to accept the request to unmute.

Do we have any other questions?

We have a question from Erik Cassel.

I hope you can hear me properly.

Very well.

Okay. Perfect. Very good. So gross margin is very impressive, once again, second quarter in a row now. And again, you mentioned that it's largely driven by sales mix. And I appreciate the color you provided on earlier Henrik. But could you provide some more info on the sort of underlying gross margin trend. I mean, say, in terms of pricing power or COGS that may be hidden by these mix changes. Just for me to sort of understand the current cost price dynamics and where we could be with the -- when the sort of sales mix normalizes?

Yes. Thanks, Erik. I mean, good question. And well, I mean, -- it is -- I mean the gross margin is really defined by the 2 factors that we point out. One is the product mix. And the products that we split out is positioning products, HIT lasers and the service products. So you can see a couple of things. One is that positioning products are a larger portion of sales as compared to HIT lasers, and there's a distinct difference here actually in the gross margin. So that is one driver behind this. Service business is a completely different business as compared to product sales. So as the service business is growing and becoming a larger part of our revenue, that also pushes revenue upwards. But the -- but then we have the product mix. The other one is the sales mix. And the difference between direct sales and distributor sales in at least certain markets is fairly distinct because obviously, the distributor will take a measurable part of the revenue for the work done. But cost of the goods sold remains the same, and we have certainly seen a growth in our U.S. market and revenue side. That's been more on the direct sales side pushing that upwards. So I think that -- if you look at the year, we end with 63%, I mean, we don't provide any guidance to it, but there is variations between the quarters. I think that the variations that we have seen during the quarter of 2021 and where it puts us on the full year is, I would say, I mean, a good estimate of our underlying gross margin. But I think it's well advised to view revenue and the gross profit combined. If you look at, I mean, fourth quarter last year, we had higher revenue growth as compared to this quarter, but part of that was driven just coming from the sales mix, but part of that went as commission to distributors.

Very good. So basically unfazed by sort of component cost increases and that sort of are you able to offset that within price increases towards your customers?

Yes. I mean a good question. And for us, the supply chain challenges have been more of managing shortage of supplies, i.e., us not getting the goods so we can deliver to the customers, not so much actually prices going upwards. And -- so again, I would say there's no real cost increases of significance in the cost of goods sold as of now, want to point that out. I mean the supply chain is, I think, an uncertainty for every company out there and of course, for us. But so far, I would say we have managed it well.

And then sales obviously held back by the pandemic this quarter. But if we were to take a look, say, month by month in Q4, did you see sales on sort of high level for October and November, but then with a softer December as Omicron sort of shaking up the world? Or was the growth of 4%, reflective of the sort of monthly run rate throughout Q4.

I think if I comment on that. I mean, in general, what we see, I mean, if we look at deliveries or revenue, I mean, in general, I mean, the main reason for the 4% this year is simply that -- I mean, last year, we had a very strong Q4, which relates to orders that came from Australia and Japan that happened to be delivered during the fourth quarter in 2020. So I think, I mean, underlying development is still very positive. I think more on the -- on the order side, there we saw effects due to the pandemic where customers -- and I would like to say that was primarily affecting the APAC region this year or last year, 2021, where customers were somehow delaying the procurement project. So it's not that they were stopped. It was more that the process to process an order at the customers took more time. Usually, the approval process was longer, and that caused a bit of a push out in terms of orders that we received. So on the delivery side, it had less of an impact.

Okay. Very good. But then if we look at installation plans for Q1, I mean, I've heard several companies talking about postponed installations, Philips, for example. Have you seen any material change to the delivery time lines? Or are you -- are they relatively intact despite the sort of hospital access issues?

So I mean it is not a major issue for us at this point in time. And what we see, however, and I want to point this out. I mean, in the majority of the cases, I mean our systems are installed as part of a larger project and larger project means together with the linear accelerator. So let's see what happens on that side if we see that there are more delays on the linac installation side, either by shortages or hospital access or the component shortages or hospital access then it might have an impact on us as well. But as of now, that was not a significant issue for us. Any other questions?

We have [ Thierry Serero ], who raised his hand.

Can you hear me?

Very well.

Yes.

Just a couple of questions. Just on the service order book, which was more or less flat year-on-year, but given that the growth was in the U.S. with less than 90% attachment, how come that the service order book wasn't growing faster than that.

I can comment on...

Okay. Henrik, go ahead.

I mean a couple of factors. One is that it depends a whole lot on the length of the service contracts that we sell when we get an order. If we sell a new system, we usually sell a service contract order as well. But as commented on that could be for 3 years or 8 years, and that obviously impacts the initial order value. So that's one factor that plays in here. And another factor is also that -- last year, we were able to equip a measurable part of our installed base that did not have service contracts with the orders then coming and filling that backlog. So that said, I mean we are content with the attachment rates and the attachments rate is I mean, how we define, I mean, we want to sell a product, and we want to attach a service contract to it. So we're good with that. But then the sort of magnitude of the order value will definitely be impacted by the 2 factors just mentioned.

Okay. Great. Just on -- is there any retrofit business at all? Or because you mentioned that as a future thing. But is there a market at all and retrofit at the moment for you?

Could you just repeat the question you were breaking up a little bit.

Sorry, bad connection. I just -- I was just wondering if you have a retrofit market at all or is it only new installation so far?

Yes. I mean, retrofit in the sense of retrofit pure existing linear accelerators. Yes, certainly. That is a part of our business as well. With that said, I mean, the large majority of the projects are going along with new linacs and that is partly depending a bit on the setup of the market. In principle, what we can say is that the private customers globally have more a tendency to upgrade or to retrofit their linac fleet over the lifetime of the machines, whereas public hospitals usually are more bound to investment budgets and that is typically coming as a larger package together with the linear accelerator and then our equipment at the same time. So -- and then looking at the different markets, obviously, U.S., which is very much of a private market there we see more of retrofits. As for example, in Scandinavia, where essentially the entire health care system is public or governmental under health care system.

But would you see at some stage an acceleration of that market? Because if it's becoming more standard of care than it should have an implied effect on the installed base.

Yes, exactly. I mean, certainly, we see a positive development there. But still, I want to emphasize, I mean, the majority is coming with new linacs at this stage.

Just a last question on the new linacs for 2021, -- could you give me an indication of what market share you had of the new installation. You mentioned that when the market is expected to be about SEK 1 billion, you would expect to have -- well, no, you didn't expect, but you made a comment about 50% market share. So I'm just trying to gauge where are we compared to the 50% market share? Are you above or below that number in '21?

Yes. I mean if we just look at the new installations, it's in the neighborhood of 10%. Now looking on the global scale, really global, including all markets and from the linac perspective, but also all markets where we have been selling.

So -- but in the U.S. or can you just give a bit more granularity about the region of your market share?

That's not an information that we are disclosing. So that's why I'm saying on a global basis, that's roughly how it looks like.

We don't have anybody else who raised their hand, but we have questions in the Q&A box. For those people, you try to raise your hand if you would like to ask a question live. We don't have any more questions.

Great. And then I would like to thank everyone for attending our webcast this morning, and I wish you a good day. Thank you very much.

Take care, everyone. Have a nice day.